Ongoing follow-up of 266 randomized patients to inform final outcomes TEWKSBURY, MA – May 14, 2026 – Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, today announced the completion of enrollment in the RESPONDER-HF clinical trial evaluating the Corvia® Atrial Shunt, with a total of 266 patients randomized. Following this […]
41% reduction in heart failure hospitalizations and significant ongoing quality-of-life improvements for responder phenotype TEWKSBURY, MA – March 3, 2026 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced positive five-year outcomes from the REDUCE LAP-HF II randomized clinical trial evaluating the Corvia® Atrial Shunt in heart failure patients with […]
Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, MA – June 17, 2025 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company’s existing investment syndicate of Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, […]
Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial BURY, MA – December 20, 2024 – Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745). The Corvia […]
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, MA – October 25, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF II randomized clinical trial confirming […]
Responder group patients with the shunt experience a 50% lower heart failure event rate and a 46% improvement in quality of life over control group TEWKSBURY, MA – August 19, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JACC-HF of two-year data from the […]
Two years of echocardiographic data affirm positive effects of atrial shunt therapy on heart structure and function TEWKSBURY, MA – May 7, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial […]
Second major trial for atrial shunt therapy demonstrates importance of patient selection TEWKSBURY, MA – April 12, 2024 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave’s RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the […]
First-ever phase III randomized controlled trial of atrial shunt therapy shows continued promise TEWKSBURY, MA – May 22, 2023 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt […]
Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, MA – December 6, 2022 Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure […]
